759 related articles for article (PubMed ID: 20862500)
1. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
[TBL] [Abstract][Full Text] [Related]
2. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease.
Ferrer I
Parkinsons Dis; 2011 Feb; 2011():708404. PubMed ID: 21403906
[TBL] [Abstract][Full Text] [Related]
3. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
4. Neurochemistry and the non-motor aspects of PD.
Ferrer I; López-Gonzalez I; Carmona M; Dalfó E; Pujol A; Martínez A
Neurobiol Dis; 2012 Jun; 46(3):508-26. PubMed ID: 22737710
[TBL] [Abstract][Full Text] [Related]
5. Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease.
Garcia-Esparcia P; Hernández-Ortega K; Koneti A; Gil L; Delgado-Morales R; Castaño E; Carmona M; Ferrer I
Acta Neuropathol Commun; 2015 Dec; 3():76. PubMed ID: 26621506
[TBL] [Abstract][Full Text] [Related]
6. Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α-synuclein.
Lang A; Dassler E; Milenkovic I; Lutz MI; Kovacs GG
Parkinsonism Relat Disord; 2021 Sep; 90():57-61. PubMed ID: 34385008
[TBL] [Abstract][Full Text] [Related]
7. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
8. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
10. Evidence of oxidative stress in the neocortex in incidental Lewy body disease.
Dalfó E; Portero-Otín M; Ayala V; Martínez A; Pamplona R; Ferrer I
J Neuropathol Exp Neurol; 2005 Sep; 64(9):816-30. PubMed ID: 16141792
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
Gomez A; Ferrer I
Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
13. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects.
Ferrer I
Prog Neurobiol; 2009 Jun; 88(2):89-103. PubMed ID: 19482226
[TBL] [Abstract][Full Text] [Related]
14. Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissues.
D'Andrea MR; Ilyin S; Plata-Salaman CR
Neurosci Lett; 2001 Jun; 306(3):137-40. PubMed ID: 11406314
[TBL] [Abstract][Full Text] [Related]
15. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease.
Ferrer I; Perez E; Dalfó E; Barrachina M
Neurosci Lett; 2007 Mar; 415(3):205-9. PubMed ID: 17284347
[TBL] [Abstract][Full Text] [Related]
16. Dopamine and α-synuclein dysfunction in Smad3 null mice.
Tapia-González S; Giráldez-Pérez RM; Cuartero MI; Casarejos MJ; Mena MÁ; Wang XF; Sánchez-Capelo A
Mol Neurodegener; 2011 Oct; 6():72. PubMed ID: 21995845
[TBL] [Abstract][Full Text] [Related]
17. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
18. Parkinson disease: from pathology to molecular disease mechanisms.
Dexter DT; Jenner P
Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
[TBL] [Abstract][Full Text] [Related]
19. Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease.
Botella JA; Bayersdorfer F; Schneuwly S
Neurobiol Dis; 2008 Apr; 30(1):65-73. PubMed ID: 18243716
[TBL] [Abstract][Full Text] [Related]
20. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.
Yu Z; Xu X; Xiang Z; Zhou J; Zhang Z; Hu C; He C
PLoS One; 2010 Apr; 5(4):e9956. PubMed ID: 20386702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
